Ahmed Nader

633 total citations
31 papers, 460 citations indexed

About

Ahmed Nader is a scholar working on Genetics, Reproductive Medicine and Dermatology. According to data from OpenAlex, Ahmed Nader has authored 31 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Reproductive Medicine and 6 papers in Dermatology. Recurrent topics in Ahmed Nader's work include Endometriosis Research and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Uterine Myomas and Treatments (5 papers). Ahmed Nader is often cited by papers focused on Endometriosis Research and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Uterine Myomas and Treatments (5 papers). Ahmed Nader collaborates with scholars based in United States, Germany and Qatar. Ahmed Nader's co-authors include Nael M. Mostafa, Peter Noertersheuser, Mohamed I. A. Othman, Mohamed‐Eslam F. Mohamed, Jacob F. Degner, Akshanth R. Polepally, Juki Ng, Jeffrey F. Waring, J. Wade Davis and David Williams and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Ahmed Nader

29 papers receiving 459 citations

Peers

Countries citing papers authored by Ahmed Nader

Since Specialization

Citations

This map shows the geographic impact of Ahmed Nader's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmed Nader with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmed Nader more than expected).

Fields of papers citing papers by Ahmed Nader

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmed Nader. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmed Nader. The network helps show where Ahmed Nader may publish in the future.

Co-authorship network of co-authors of Ahmed Nader

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmed Nader. A scholar is included among the top collaborators of Ahmed Nader based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmed Nader. Ahmed Nader is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Traces of cardioprotection behind the uncertainty of the de winter pattern 2025 ·Journal of Electrocardiology ·(unknown), Ahmed Nader, (unknown), Babak Bagheri, (unknown)	0
2	Population pharmacokinetic and exposure‐response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis 2023 ·British Journal of Clinical Pharmacology ·Mohamed A. Ismail, (unknown), (unknown), Alan D. Irvine, Alvina D. Chu, Henrique D. Teixeira, (unknown), Ahmed Nader	10
3	Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (Phase 2b B-Clear study) 2023 ·Journal of Hepatology ·Jérôme Bouquet, Robert C. Elston, Phil Yates, Shihyun You, (unknown), Ahmed Nader, Jennifer Cremer, Gwendolyn P. Quinn, Fiona Campbell, Melanie Paff, Dickens Theodore	1
4	Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial 2022 ·The Lancet Rheumatology ·R. Fleischmann, Alan Friedman, Edit Drescher, Atul Singhal, Gregorio Cortes-Maisonet, Thao Doan, Wenjing Lü, Zailong Wang, Ahmed Nader, William Housley, Stanley Cohen, Peter C. Taylor, Ricardo Blanco	8
5	Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis 2021 ·Clinical and Translational Science ·Sven Stodtmann, Ahmed Nader, Akshanth R. Polepally, Ahmed A. Suleiman, (unknown), Peter Noertersheuser, Juki Ng, Nael M. Mostafa, Mohamad Shebley	3
6	Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model 2020 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Akshanth R. Polepally, Ahmed Nader, Nael M. Mostafa, Peter Noertersheuser, Juki Ng	3
7	Drug–Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy 2020 ·Clinical Pharmacokinetics ·Ahmed Nader, Nael M. Mostafa, (unknown), Mohamad Shebley	9
8	A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2 2019 ·Journal of Investigative Dermatology ·(unknown), Jacob F. Degner, Robert W. Georgantas, Ahmed Nader, Nael M. Mostafa, Henrique D. Teixeira, David Williams, Robert S. Kirsner, Anna Nichols, J. Wade Davis, Jeffrey F. Waring	20
9	Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus 2019 ·Clinical Pharmacokinetics ·Ahmed Nader, Mukul Minocha, Mohamed I. A. Othman	5
10	Clinical and Pharmacokinetic Outcomes of Peak–Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial 2019 ·European Journal of Drug Metabolism and Pharmacokinetics ·(unknown), Ahmed Nader, Mohamed Saad, (unknown), (unknown), (unknown), Daoud Al‐Badriyeh, Hazem Elewa, Ahmed Awaisu	36
11	Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for Endometriosis 2019 ·Clinical Pharmacokinetics ·Mohamad Shebley, Akshanth R. Polepally, Ahmed Nader, Juki Ng, (unknown), Cheri E. Klein, Peter Noertersheuser, Megan Gibbs, Nael M. Mostafa	45
12	A rare case of methotrexate and primaquine co‐administration in a mantle cell lymphoma patient 2019 ·Journal of Clinical Pharmacy and Therapeutics ·Alan L. Myers, Jitesh D. Kawedia, Ahmed Nader, Jason R. Westin, (unknown)	0
13	Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials 2019 ·The Journal of Clinical Pharmacology ·Ahmed Nader, Sven Stodtmann, (unknown), Mohamed‐Eslam F. Mohamed, Mohamed I. A. Othman	34
14	Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis 2019 ·Clinical Pharmacology & Therapeutics ·Ahmed Nader, Mohamed‐Eslam F. Mohamed, (unknown), (unknown), Peter Noertersheuser, Aileen L. Pangan, Mohamed I. A. Othman	25
15	Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis 2018 ·Clinical Pharmacokinetics ·(unknown), Ahmed Nader, Akshanth R. Polepally, Mohan Liu, Jacob F. Degner, Cheri E. Klein, Nael M. Mostafa, Peter Noertersheuser, Juki Ng	23
16	Identification of HLA-DRB1 association to adalimumab immunogenicity 2018 ·PLoS ONE ·(unknown), Jacob F. Degner, J. Wade Davis, Kenneth B. Idler, Ahmed Nader, Nael M. Mostafa, Jeffrey F. Waring	49
17	Assessment of disinfection by-products levels in Aga surface water plant and its distribution system, Dakhlia, Egypt 2017 ·International Journal of Advanced Research in Biological Sciences (IJARBS) ·(unknown), (unknown), (unknown), Ahmed Nader	3
18	Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa 2017 ·Clinical Pharmacokinetics ·Ahmed Nader, (unknown), Peter Noertersheuser, David Williams, Nael M. Mostafa	33
19	Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters 2016 ·European Journal of Drug Metabolism and Pharmacokinetics ·Ahmed Nader, (unknown), (unknown), (unknown), (unknown), Kyle John Wilby	29
20	Suitability of digoxin as a P‐glycoprotein probe: Implications of other transporters on sensitivity and specificity 2013 ·The Journal of Clinical Pharmacology ·Ahmed Nader, (unknown)	27

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact